Please login to the form below

Not currently logged in
Email:
Password:

Supreme Court to hear vaccine safety appeal

Justices will hear an appeal to determine if lawusit cases involving vaccine side-effects in children can be heard outside the protective judicial forum

Justices have agreed to hear an appeal to determine whether drug makers can be sued outside of the protective judicial forum set up by Congress in 1986 over claims that their vaccines caused side-effects in children.

Since 1986, the designated judicial forum or so-called 'vaccine court' has handled such disputes and was designed to ensure a reliable, steady supply of the drugs by reducing the threat of lawsuits against pharmaceutical firms.

The question in this case is whether such liability claims can proceed if the vaccine-related injuries could have been avoided by better product design and if federal officials had approved another, safer drug.

The appeal was brought by parents in Pennsylvania who filed a case against Pfizer's Wyeth unit claiming that the company's diphtheria, tetanus and whooping cough vaccine caused their child to develop residual seizure disorder.

The parents alleged Wyeth failed to adequately warn them and other parents of the risks associated with the vaccine. The vaccine court rejected the initial claim. The parents then took the case to the federal court, but it also ruled in favour of Wyeth, concluding all design-defect claims were barred under statute.

Pfizer, however, have urged the high court to hear the case to seek resolution on broader legal questions. The Obama administration is also urging a review, but is supporting the company and federal law in question.

The court is expected to make its decision in the upcoming term, which starts in October.

9th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics